Can I Take Omega-3 (EPA/DHA) With BPC-157?

Import from '@/components/mdx'

The short answer: low risk, but not zero

Taking omega-3 fish oil alongside BPC-157 is unlikely to cause a clinically significant problem for most healthy women at standard supplement doses. The concern that exists is pharmacodynamic, meaning both agents may independently reduce platelet aggregation, and using them together could add those effects rather than multiply them. There is no known pharmacokinetic interaction: omega-3 fatty acids do not meaningfully alter how BPC-157 is absorbed, distributed, or cleared, and BPC-157 does not change how EPA or DHA is metabolized.

The honest caveat here is substantial. BPC-157 (body protection compound-157, a synthetic pentadecapeptide derived from a gastric juice protein) has almost no controlled human trial data. Most mechanistic work comes from rodent models. This evidence gap is relevant for every woman reading this, and it is covered in detail below.

What BPC-157 is and why women are using it

BPC-157 is a 15-amino-acid peptide derived from human gastric juice protein BPC. It is available in the United States only through 503A compounding pharmacies and is not FDA-approved for any indication. Women are increasingly using it for tendon and ligament repair after injury, gut permeability issues, post-surgical recovery, and, in some functional medicine circles, hormonal symptom management, though that last application has essentially no direct human evidence.

How BPC-157 works (mechanistically)

Animal studies suggest BPC-157 accelerates tissue healing through several pathways: upregulation of growth hormone receptor expression, promotion of angiogenesis via nitric oxide and VEGF modulation, and attenuation of inflammatory cytokine activity. One frequently cited rodent study showed accelerated tendon-to-bone healing with systemic BPC-157 compared to controls. The peptide also appears to modulate dopaminergic and serotonergic signaling in animal models, which is why some practitioners discuss it for mood and gut-brain axis support.

The antiplatelet signal in BPC-157

Here is where the omega-3 overlap becomes relevant. Several animal studies have noted that BPC-157 influences nitric oxide (NO) pathways. Nitric oxide inhibits platelet aggregation by elevating cyclic GMP in platelets, reducing their activation. If BPC-157's NO-modulatory activity extends to human platelet function, it could theoretically reduce clotting efficiency. No human platelet aggregation study for BPC-157 has been published as of this article's review date.

How omega-3 (EPA/DHA) affects platelets and bleeding time

Omega-3 fatty acids are among the most studied supplements for cardiovascular and anti-inflammatory effects. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) reduce platelet aggregation through at least two mechanisms: competing with arachidonic acid for cyclooxygenase enzymes (which decreases thromboxane A2 production) and incorporating into platelet membranes to reduce membrane rigidity and activation sensitivity.

A meta-analysis published in Prostaglandins, Leukotrienes and Essential Fatty Acids found that fish oil supplementation prolonged bleeding time in a dose-dependent fashion, with more consistent effects at doses above 3 g/day of combined EPA+DHA. At the 1-2 g/day doses used by most women for general cardiovascular or anti-inflammatory support, the antiplatelet effect is measurable in vitro but rarely clinically significant in women without baseline coagulation disorders.

The FDA has acknowledged that doses above 3 g/day of EPA+DHA may affect bleeding time, which is why this threshold appears on many product labels. Prescription-strength omega-3 formulations such as icosapentaenoic acid (Vascepa, 4 g/day) carry specific prescribing notes about antiplatelet effects.

What the combination means in practice

The working concern is additive, not synergistic. If BPC-157 does reduce platelet activation through NO pathways (as suggested by animal data) and omega-3 reduces thromboxane A2-driven aggregation, a woman taking both is potentially stacking two mild antiplatelet mechanisms. This is almost certainly less consequential than, say, combining aspirin with omega-3, where one agent directly irreversibly inhibits COX-1. Still, it is worth quantifying your personal risk:

• If you take 1-2 g/day omega-3 and standard BPC-157 doses (200-500 mcg subcutaneous or oral, which are the most common compounded ranges), bleeding risk elevation is likely minimal.
• If you take 3-4 g/day omega-3 and are also on any anticoagulant, antiplatelet medication, or NSAIDs, the combination deserves a direct conversation with your prescriber before continuing.
• If you are preparing for any surgery, stop both at least 7-10 days beforehand, consistent with ACOG guidance on supplements and surgical risk.

Sex-specific physiology: why women need different guidance

Women's platelet biology is not simply a smaller version of men's. Female platelets are more reactive on average, a difference that varies with estrogen status across the menstrual cycle, pregnancy, and menopause. One study in the journal Thrombosis and Haemostasis found platelet aggregation to be highest in the luteal phase, when progesterone is elevated. This means that the antiplatelet overlay from omega-3 and potentially BPC-157 could behave differently depending on where you are in your cycle.

Reproductive years and the menstrual cycle

If you notice heavier periods or prolonged bleeding after starting either supplement, that is a signal worth taking seriously. Women with fibroids or adenomyosis are at baseline higher risk for heavy menstrual bleeding, and layering antiplatelet supplements on top of an already heavy cycle is not a neutral act. Tracking cycle length and flow volume using a validated tool like the pictorial blood assessment chart is reasonable if you are using both supplements long-term.

PCOS

Women with PCOS have a well-documented increased risk of both cardiovascular disease and chronic low-grade inflammation. Omega-3 supplementation at 2-4 g/day has shown modest benefit in reducing triglycerides and inflammation markers in women with PCOS. BPC-157 use in PCOS is anecdotal and unstudied. Given that women with PCOS often have higher baseline platelet activity related to insulin resistance and androgen excess, tracking bleeding symptoms when combining these two agents is especially relevant.

Perimenopause and postmenopause

Estrogen decline reduces the protective cardiovascular effects of estrogen on platelet function and endothelial health. Many perimenopausal women are concurrently using omega-3 for cardiovascular support and mood, and some are exploring BPC-157 for joint pain and tissue repair as collagen synthesis slows. The antiplatelet interaction concern does not disappear after menopause, though the monthly bleed-risk angle does. Cardiovascular bleeding risk (from, say, GI bleeding or easy bruising) becomes the more relevant monitoring target.

Pregnancy, lactation, and contraception: required reading

BPC-157 is contraindicated in pregnancy. There are no human safety data for BPC-157 in pregnancy, and animal developmental toxicity studies have not been conducted to the standard required for human use. As a compounded, unapproved peptide with no FDA pregnancy category, it should be stopped before attempting conception and must not be used during pregnancy or while breastfeeding. Any woman of reproductive age using BPC-157 should use reliable contraception while on it.

Omega-3 (EPA/DHA) has a very different safety profile during pregnancy. ACOG recommends that pregnant women consume at least 200-300 mg of DHA per day, and fish oil supplementation is widely considered safe across all trimesters when used at typical doses. A 2019 Cochrane review of omega-3 supplementation in pregnancy found that omega-3 supplementation reduced the risk of preterm birth before 37 weeks (risk ratio 0.89) and improved birth weight outcomes.

Bottom line for pregnancy: Stop BPC-157 immediately if you are pregnant, trying to conceive, or breastfeeding. Continue omega-3 supplementation as directed by your OB or midwife. Do not restart BPC-157 until you have finished breastfeeding and have discussed it with a clinician who is familiar with peptide compounding.

For lactation specifically, no transfer data exists for BPC-157 in breast milk. Given the complete absence of safety data, BPC-157 use while breastfeeding is not supported.

Pharmacokinetic considerations: will one change how the other works?

Short answer: almost certainly not. Omega-3 fatty acids are metabolized by beta-oxidation in mitochondria and via cytochrome P450 omega-oxidation pathways. BPC-157, as a peptide, is broken down by proteases in circulation and tissues into amino acids. These are entirely separate metabolic pathways. CYP enzyme-based drug interactions are not expected with either agent, and no published human pharmacokinetic study has examined a BPC-157 drug interaction of any kind.

The separation you may read about online, taking BPC-157 on an empty stomach and omega-3 with food, is based on practical absorption optimization for each compound independently, not on avoiding an interaction window. BPC-157 (when taken orally) is theorized to be more stable in a low-acid environment, though this is speculative. Omega-3 is better absorbed with fat-containing meals. Following those individual instructions is reasonable but is not a strategy for managing the antiplatelet concern.

Who this is and is not right for

Women for whom combining BPC-157 and omega-3 is relatively lower risk

• You are in your reproductive years, not pregnant, not planning pregnancy soon, and using reliable contraception.
• Your omega-3 dose is 1-2 g/day of combined EPA+DHA.
• You do not have a personal or family history of bleeding disorders.
• You are not taking anticoagulants (warfarin, apixaban, rivaroxaban), prescription antiplatelet drugs (clopidogrel, aspirin at doses above 81 mg/day), or NSAIDs regularly.
• You have discussed BPC-157 with a clinician who has reviewed your full medication list.

Women for whom this combination deserves close monitoring or avoidance

• You have fibroids, adenomyosis, or a history of heavy menstrual bleeding.
• You have a diagnosed coagulation disorder (e.g., von Willebrand disease, platelet function disorder).
• You are perimenopausal and on hormone therapy that may already affect clotting (for example, oral estrogen-containing regimens carry a small independent VTE risk).
• You take omega-3 at doses of 3 g/day or higher.
• You are within 2 weeks of any planned surgical procedure.
• You are pregnant, trying to conceive, or breastfeeding: stop BPC-157 entirely.

Dosing and monitoring guidance

There is no official dosing standard for BPC-157 because it is not FDA-approved. Compounded doses most commonly prescribed through 503A pharmacies range from 200 to 500 mcg per day, either subcutaneously injected or taken orally as a capsule. Some practitioners use higher doses. The absence of human dose-finding trials means there is no established therapeutic window and no established safety ceiling.

For omega-3, the American Heart Association recommends 1 g/day of EPA+DHA for adults with documented coronary heart disease, while doses of 2-4 g/day are used under physician supervision for hypertriglyceridemia. Women managing PCOS-related dyslipidemia often fall in the 2-3 g/day range.

If you are using both supplements, practical monitoring steps include:

• Noting any new bruising, prolonged bleeding from cuts, or nosebleeds in the first 4-8 weeks.
• Tracking menstrual flow if you are premenopausal, because heavier periods are an early clinical signal of additive antiplatelet activity.
• Asking your prescriber to check a CBC with platelet count if you are using high-dose omega-3 (3 g/day or more) along with BPC-157 for more than 3 months.
• Reporting any symptoms to your compounding pharmacist, who can consult with the prescribing clinician.

The evidence gap: what we do not know

As of the most recent systematic review of BPC-157 literature, there are no completed, peer-reviewed randomized controlled trials in humans for BPC-157 for any indication. The bulk of mechanistic data comes from rat and mouse models, which do not always translate cleanly to human physiology, and essentially never translate cleanly to female human physiology across all hormonal states.

Women have historically been under-represented in clinical trials, including those studying compounded peptides and dietary supplements. No published study has examined BPC-157 pharmacokinetics, efficacy, or safety specifically in women. No study has examined how menstrual cycle phase, pregnancy, perimenopause, or hormone therapy changes BPC-157 behavior. Every recommendation in this article regarding sex-specific effects is extrapolated from adjacent mechanistic data, not directly studied. This is a meaningful gap, and any clinician who tells you otherwise is overstating the evidence.

The honest clinical position, as noted by WomanRx Medical Reviewer Dr. Maya Okafor, MD:

"BPC-157 is one of the more commonly requested compounded peptides I see in women's health right now. The animal science is genuinely interesting. But I tell every patient: we are working with almost no human data, and zero sex-stratified data. Combining it with omega-3 is probably not dangerous at standard doses, but 'probably not dangerous' is a different statement from 'proven safe.' Women deserve to know that distinction before they sign a compounding consent form."

This framing should anchor your own decision-making. "Probably not dangerous" is where the evidence sits today.

Practical steps if you are already taking both

If you started omega-3 and BPC-157 together before reading this and feel fine, you do not need to panic. Do the following:

1. Confirm your omega-3 dose. If it is under 2 g/day EPA+DHA combined, you are in the lower-risk range for additive antiplatelet effects.
2. Review your full medication list with a pharmacist or clinician. Any prescription blood thinner, NSAID, or antiplatelet drug changes the calculus significantly.
3. Track your periods for two full cycles. Increased flow or spotting between periods warrants a provider call.
4. If you are approaching any surgical or dental procedure, stop both supplements 7-10 days before and tell the surgical team what you were taking.
5. If you are or become pregnant, stop BPC-157 immediately. Omega-3 should continue per your obstetric provider's guidance.

The FDA's MedWatch program is the appropriate reporting channel if you experience an unexpected adverse event from a compounded peptide.